Market Overview

CIBC Analysts On Valeant: Questions Still Unanswered After Investor Day

CIBC Analysts On Valeant: Questions Still Unanswered After Investor Day
Related VRX
Benzinga's Bulls & Bears Of The Week: Amazon, Costco, Netflix, Tesla And More
Dear Activists: Buying Stock Can Effect More Change Than Selling It
FDA OKs Sun Pharma's Ilumya for plaque psoriasis (Seeking Alpha)
Related WBA
Checking In On The Healthcare Sector Ahead Of Q1 Earnings Season
4-Time NBA Champion John Salley Talks About His Cannabis Ventures
10 Dividend Growth Stocks For March 2018 (Seeking Alpha)
  • Valeant Pharmaceuticals Intl Inc (NYSE: VRX) recently held its Investor Day, where management provided revised guidance, in line with estimates.
  • Following the event, CIBC analysts Prakash Gowd and Ryan Lee issued a Sector Perform rating and $90 price target on the shares.
  • The experts commented they still had unanswered questions regarding the company’s relationship with Walgreens Boots Alliance Inc (NASDAQ: WBA).

After attending Valeant’s Investor Day, analysts at CIBC noted that a few questions remained unanswered – especially those regarding the company’s 20-year deal to cut prices for Walgreens.

Related Link: Valeant Paring Gains From Recent Rally

Below are the three main questions to which the experts found no answer.

1. Philidor

The new fulfillment agreements help make up for the lost Philidor revenue, while providing a venue for the company’s patient assistance program. Nonetheless, margins for these sales are lower – but management would not comment on this issue other than to say their internal assumptions are conservative.

2. Walgreens

The analysts do not fully understand why Valeant opted for the Walgreens agreement instead of going for another "specialty pharmacy" deal. Coincidentally, the experts noted, during CVS Health Corp (NYSE: CVS)’s Investor Day, management said that 90 percent of Valeant’s products were either “excluded from its formulary or considered ‘non-preferred.’” Valeant declined to comment on this, but CIBC analysts “wonder if the company's relationship with PBMs has been negatively impacted by pricing issues and the Philidor problems.”

3. Copay Assistance

The experts believe that sales through other pharmacy channels will see a decline since customers will be able to purchase the same drugs at Walgreens, at lower prices and with copay assistance – Valeant does not offer the program through other pharmacy channels for now.

Disclosure: Javier Hasse holds no positions in any of the securities mentioned above.

Image Credit: Public Domain

Latest Ratings for VRX

Mar 2018Deutsche BankUpgradesHoldBuy
Jan 2018Goldman SachsInitiates Coverage OnSell
Dec 2017JP MorganDowngradesNeutralUnderweight

View More Analyst Ratings for VRX
View the Latest Analyst Ratings

Posted-In: Analyst Color Biotech Long Ideas Health Care Price Target Reiteration Top Stories Analyst Ratings


Related Articles (CVS + VRX)

View Comments and Join the Discussion!